Summary An antigen of apparent molecular weight of 24000, reactive with a murine monoclonal antibody, has been isolated from a cachexia-inducing tumour (MAC 16) and has been shown to initiate muscle protein degradation in vitro using isolated soleus muscle. Administration of this material to female NMRI mice (20 g) produced a pronounced depression in body weight (2.72 ± 0.14 g; P<0.005 from control) over a 24 h period. This weight loss was attenuated in mice pretreated with the monoclonal antibody (0.06 + 0.26 g over 24 h) and occurred without a reduction in food and water intake. There was no change in body water composition, and the major contribution to the decrease in body weight was a decrease in the non-fat carcass dry weight (mainly lean body mass). The plasma levels of glucose and most amino acids were also significantly depressed. The decrease in lean body mass was accounted for by an increase (by 50%) in protein degradation and a decrease (by 50%) in protein synthesis in gastrocnemius muscle. Protein degradation was significantly decreased and protein synthesis increased to control values in mice pretreated with the monoclonal antibody. Protein degradation initiated in vitro with the proteolysis-inducing factor was abolished in mice pretreated with eicosapentaenoic acid (EPA), which had been shown to prevent muscle wastage in mice bearing the MAC16 tumour. Protein degradation was associated with a significant elevation of prostaglandin E2 production by isolated soleus muscle, which was inhibited by both the monoclonal antibody and EPA. These results suggest that this material may be the humoral factor mediating changes in skeletal muscle protein homeostasis during the process of cancer cachexia in animals bearing the MAC16 tumour, and could potentially be involved in other cases of cachexia.
Cachexia is the most common adverse systemic effect of malignancy, affecting up to 50% of all untreated cancer patients and is an important determinant in their overall survival (De Wys et al, 1980) . Loss of adipose tissue and particularly skeletal muscle mass during the process of cachexia leads to weakness and an increased susceptibility to infection, with a 30% loss in body weight proving fatal (Brennan, 1977) . In cancer cachexia weight loss arises equally from muscle and fat, in contrast to starvation, in which case three-quarters of the weight is lost from fat and only a small amount from muscle (Cohn et al, 1981) . Thus, for a given degree of weight loss, there is more wasting of muscle in a cancer patient than in a normal subject. Body composition analysis of patients with cancer and those with anorexia nervosa using 40K counting have shown that the former lose a greater proportion of body cell mass, even though the total body weight loss may be only one-half of that of patients with anorexia (Moley et al, 1987) . Although the total skeletal muscle mass decreases during the process of cachexia, loss of white muscle exceeds that of red muscle (Clark and Goodlad, 1971) . Wasting of peripheral muscle may be due to increased muscle catabolism or decreased protein synthesis, or a combination of the two. A decrease in protein synthesis has been observed in human rectus abdominis muscle from cancer patients when compared with age-matched control subjects (Lundholm et al, 1976) . In patients with hepatocellular carcinoma, the high protein turnover rates were found to be due to elevated protein Received 23 January 1997 Revised 1 April 1997 Accepted 4 April 1997 Correspondence to: MJ Tisdale breakdown and oxidation of amino acids (O'Keefe et al, 1990) . As loss of muscle often precedes a fall in food intake (Costa, 1963) , a number of studies have been directed towards the identification of the factor responsible for changes in protein balance in skeletal muscle.
Several factors have been suggested as signals for the increased muscle proteolysis including tumour necrosis factor alpha (TNFa) and interleukin 1 (IL-1) and 6 (IL-6). In vivo studies have shown muscle proteolysis to be significantly increased by TNF-a and synergistically increased when combined with IL-1,B (Flores et al., 1989) . However, Goldberg et al (1988) were unable to detect a catabolic effect of TNF-a, IL-la or IL-1, singly, or together, after incubation of skeletal muscle in vitro, suggesting that the effects of the cytokines on protein balance in skeletal muscle may be triggered by an intermediatory unknown factor. This appears not to be IL-6 as recombinant human material did not affect either the rate of protein synthesis or stimulate protein breakdown in rat skeletal muscle (Garcia-Martinez et al., 1994) .
Our own studies using the MAC 16 murine cachexia model have also provided evidence for a proteolysis-inducing factor in the serum of animals with weight loss (Smith and Tisdale, 1993a) . This material has been shown to be a proteoglycan or glycoprotein of apparent molecular weight of 24 000, which is present not only in the MAC 16 tumour, but also in the urine of cachectic cancer patients (Todorov et al, 1996a) . The material produced a state of cachexia when administered to non-tumour-bearing animals and was capable of inducing a catabolic state in gastrocnemius muscle in vitro (Todorov et al, 1996b) . The present report provides further information on the effect of this material on skeletal muscle protein homeostasis both in vitro and in vivo. (Beck and Tisdale, 1987) . Tumours were excised from mice with weight loss between 20 and 25% and used to prepare the proteolysis inducing factor. 
Purification of proteolysis-inducing factor
Solid MAC 16 tumours were homogenized followed by ammonium sulphate (40%, w/v) precipitation, and the supematant was subjected to affinity chromatography using a monoclonal antibody purified as described previously (Todorov et al., 1996b) . The immunogenic fractions were subject to hydrophobic chromatography using a Brownlee Aquopore RP-300 C8 column using an Body composition analysis Each carcass was placed in an oven at 800C until constant weight was reached. Carcasses were then reweighed and the total fat content was determined by the method of Lundholm et al (1980) .
The residue was the non-fat mass. The water content was calculated from the wet and dry weights. Results are expressed as means ± s.e.m. for four animals per group and differences from the control group were determined by Student's t-test and are indicated as ap < 0.05, bp < 0.01 and c P < 0.005.
Tyrosine release assay
Mice were injected i.v. with the proteolysis-inducing factor as described in the figure legends, and after 24 h the soleus muscles were ligated by the tendons, dissected out intact and placed in icecold isotonic saline. They were then quickly ligated to stainlesssteel supports under slight tension, which resembled that observed at resting length in vivo, and incubated for 2 h in Krebs-Henseleit buffer containing 6mM D-glucose, 1.2 mg ml-' bovine serum albumin and 130 gg ml' cycloheximide with continuous gassing.
At the end of the incubation, the buffer was removed, deproteinized with ice-cold 30% trichloroacetic acid (0.2 ml), centrifuged at 2800 g for 10 min and the supernatant was used for the measurement of tyrosine by a fluorimetric method (Waalkes and Udenfriend, 1957) at 570 nm on a Perkin-Elmer LS-5 luminescence spectrometer. Tyrosine is present in most proteins and is neither synthesized nor metabolized by skeletal muscle and therefore gives a reasonable estimate of total protein degradation. after in vivo administration according to the protocol described in the legend to Table 2 . One group of mice was pretreated with the monoclonal antibody (Ab) (0.8 mg protein) 24 h before the administration of the factor whereas the control group received PBS. Results are expressed as means + s.e.m. for four animals per group. In the treated group, differences from the control group were determined by Student's t-test and are indicated as a P 0.05 whereas in the antibody group differences from the treated group are indicated as a P < 0.05 and b P < 0.01
However, it does not distinguish between the breakdown of total and myofibrillar proteins.
Prostaglandin E2 determination
The soleus muscles were removed from NMRI female mice 24 h after the first injection of the proteolysis-inducing factor and incubated for 2 h in Krebs-Henseleit buffer as for tyrosine release. For in vitro studies, muscles were preincubated for 30 min in RPMI-1640 medium without phenol red containing normal mouse serum (7%) with or without the proteolysis-inducing factor. The muscles were rinsed three times, the medium replaced by Krebs buffer and the incubation was continued for a further 1.5 h. A portion (100 R1) of the soleus muscle incubation medium was mixed with [5,6,8,11,12,14,15-3H(N) (Todorov et al. 1996a ), which could be further fractionated by reversed-phase high performance liquid chromatography (HPLC) . The material of molecular weight 24 000 appears to be a proteoglycan or sulphated glycoprotein (Todorov et al., 1996a) that binds tightly to mouse albumin to form a complex of apparent molecular weight 69 000. The material was capable of direct induction of protein degradation in isolated soleus muscle as measured by tryrosine release (Figure 1 ). High concentrations of the material were inhibitory to protein degradation, resulting in a bell-shaped dose-response curve similar to that observed with serum from mice bearing the MAC 16 tumour and increasing weight loss (Smith and Tisdale, 1993b) . To determine the pharmacokinetics of the material of apparent molecular weight 24 000 before in vivo administration, HPLCpurified antigen was labelled with 1251 and the labelled material was administered i.v. to female NMRI mice bearing the MAC16 tumour (Figure 2 ). There was a rapid disappearance of label from the blood (t 12 of a phase, 36 min), followed by a second slower elimination rate (t 12 of 3 phase, 25.3 h). Most of the radioactivity (37%) appeared in the urine within the first 24 h, with only a small amount (0.3%) in faeces and less than 3% being retained by the individual organs and tumour (Table 1 ). In view of the rapid elimination rate, antigen was administered to non-tumour-bearing mice at 1.5-h intervals (four doses over a 6 h period) and the effect on body weight and body composition was determined. The results presented in Table 2 show a significant decrease in body weight in mice receiving antigen, which was attenuated by prior administration of the monoclonal antibody. There was no reduction in food or water intake associated with the weight loss ( Table 2) . Body composition analysis showed a significant reduction in the carcass dry weight without a change in body water composition. Carcass dry weight was increased up to control values in mice pretreated with the monoclonal antibody. Blood glucose levels were also decreased (Table 2 ). In addition, there was a significant decrease in the plasma levels of threonine, serine, proline, glycine, alanine, methionine, isoleucine, leucine, lysine, tryptophan and histidine (Table 3) .
British Journal of Cancer (1997) 76(8), 1035-1040
Despite this decrease in plasma amino acid levels, there was an increase (by 50%) in protein degradation and a decrease (by 50%) in protein synthesis in gastrocnemius muscle 24 h after the administration of the antigen as determined by L-[4-3H]phenylalanine labelling ( Figure 3 and Table 4 ). Protein degradation was significantly decreased and protein synthesis increased in mice pretreated with the monoclonal antibody such that the values were not significantly different from the control group. The effect of the antigen on protein synthesis in heart, kidney, spleen and liver is shown in Table 4 . There was no significant depression in protein synthesis in other host organs at dose levels that produced a profound depression of protein synthesis in skeletal muscle. In fact, in heart, liver and spleen there was a tendency for an increase in protein synthesis, but this did not reach significant levels. There was no effect on the acid soluble pool of [3H]phenylalanine except in spleen, where there was a significant elevation in the presence of antigen (Table 4) . Protein degradation was also significantly elevated in soleus muscle 24 h after antigen administration as measured by tyrosine release ( Figure 4A ) and this effect was attenuated in mice pretreated with the monoclonal antibody. Induction of protein degradation in soleus muscle was accompanied by a significant elevation of prostaglandin E2 (PGE2) production during the incubation period, which was completely inhibited in mice pretreated with the monoclonal antibody ( Figure 4B ). An increased tyrosine release was not seen in muscles isolated from mice previously dosed for 24 h with the polyunsaturated fatty acid, eicosapentaenoic acid (EPA) ( Figure SA) . The increase in protein degradation was again accompanied by an elevation of PGE2, which was reduced down to control values in muscles from mice treated with EPA ( Figure SB) . This suggests that PGE2 may be the intracellular mediator of the induction of proteolysis by the material of apparent molecular weight 24 000.
DISCUSSION
This study shows that a material of apparent molecular weight 24 000 isolated from a cachexia-inducing tumour (MAC 16), when administered to non-tumour-bearing mice, induces a state of cachexia similar to that produced by the tumour (Beck and Tisdale, 1987) . The major compartment of weight loss is lean body mass and this is due to an inhibition of protein synthesis and an increase in protein degradation in skeletal muscle. Previous studies have shown a depression in protein synthesis and an increase in protein degradation in skeletal muscle of mice bearing the MAC 16 tumour (Beck et al, 1991) . Unlike the effect of the cytokines TNFa, IL-1 and IL-6 the material of molecular weight 24 000 was not only capable of increasing protein degradation after administration in vivo, but also caused protein degradation in vitro, using isolated whole muscle. This suggests a direct effect of this material on skeletal muscle protein homeostasis.
We have previously shown a rise in the PGE2 level of gastrocnemius muscle after incubation with serum from cachectic mice bearing the MAC16 tumour, conditions that lead to an elevated protein degradation (Smith and Tisdale, 1993b) . Induction of muscle protein degradation by the proteolysis-inducing factor was also associated with a rise in muscle PGE2 production. This appeared to be causally related to the process, as inhibition of protein degradation by an antibody to the proteolysis-inducing factor or by pretreatment of the mice with EPA, which has been shown to reduce protein degradation in mice bearing the MAC16 (50 ,ul) . After 24 h muscles were excised and used for the experiment as described in Materials and methods. Values for muscles that were incubated with mouse serum alone have been subtracted from the values shown, which are given as means ± s.e.m. Differences between the EPA treated and non-treated groups are indicated as b P < 0.01 tumour (Beck et al., 1991) , caused an inhibition of PGE2 production. These results suggest that PGE2 may be the intracellular mediator of the proteolytic process induced by the proteolysisinducing factor. The role of PGE2 in muscle protein degradation is controversial. Thus Rodemann and Goldberg (1982) were the first to show that PGE2 and arachidonic acid were able to stimulate protein degradation in isolated rat skeletal and atrial muscle. Other studies have shown PGF2a to activate synthesis of muscle proteins (Reeds et al, 1985) and arachidonate to stimulate (Palmer and Wahle, 1987) or inhibit protein synthesis (Rotman et al, 1985) , without affecting protein degradation. Some studies suggest that TNFa alone, or in combination with IL-1 (Flores et al, 1989; Hellerstein et al, 1989) , increases protein degradation through a prostaglandin intermediate in vivo. Experiments using the Yoshida ascites hepatoma, a tumour associated with a marked activation of muscle protein degradation, show that administration of inhibitors of prostaglandin synthesis including naproxin (Strelkov et al, 1989) and acetylsalicylic acid (Tessitore et al, 1994 ) also inhibit the elevated muscle catabolism. However, the role of PGE2 in muscle protein degradation has remained controversial (Palmer, 1990) . In particular, arachidonate or PGE2 has not been shown to affect total or myofibrillar protein degradation under a variety of British Journal of Cancer (1997) 76(8), 1035-1040 b conditions in vitro and the cyclo-oxygenase inhibitor indomethacin does not affect protein degradation in septic rats in vivo (Hasselgren et al, 1990) . Thus, the role of PGE2 in the signal transduction pathways involved in protein degradation requires further studies.
Despite the extensive loss of lean body mass 24 h after in vivo administration of the proteolysis-inducing factor, plasma levels of threonine, serine, proline, glycine, alanine, methionine, isoleucine, leucine, lysine, trypophan, histidine and glucose were found to be decreased. We have previously reported decreased serum levels of threonine, serine, glycine, alanine, valine, isoleucine, leucine, lysine, methionine, tyrosine, histidine (Beck and Tisdale, 1989) and glucose (McDevitt and Tisdale, 1992) in cachectic mice bearing the MAC16 tumour. Most investigators have also noted widespread decreases in plasma levels of free amino acids in patients with cachexia. Thus, a study of Norton et al (1985) of patients with oesophageal carcinoma and with 22% weight loss showed decreased fasting plasma levels of threonine, serine, proline, glycine, alanine, tyrosine, phenylalanine, lysine, histidine, arginine and aspartate. Another study of weight-losing cancer patients with about 7% weight loss showed decreased alanine, glutamate, threonine, serine, proline and histidine (Clarke et al, 1978) . The reason for this apparent anomaly is unknown, but it could result from an increased utilization of amino acids or an increased elimination in the urine.
Previous studies have reported a depression of protein synthesis in skeletal muscle after implantation of the Ehrlich ascites tumour, which was not a consequence of the metabolic demands, providing evidence for the production of a humoral factor by the tumour (Lopes et al, 1989 ). The present study has shown a proteolysisinducing factor to be capable of inhibiting protein synthesis in skeletal muscle and this, together with the increase in protein degradation, provides evidence that it is the humoral factor associated with cancer cachexia.
